NCI-2023-00614

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy.

This Phase 3 research study is investigating the effectiveness of a new cancer drug called Dato-DXd, either alone or in combination with another drug called durvalumab. The study focuses on patients with early-stage triple-negative breast cancer that has not been completely eliminated by surgery and chemotherapy. They want to see if these treatments can help these patients more effectively.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

triple-negative: It is a type of breast cancecancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

early-stage: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05629585

Clinical Trial Site: Sinai

To see all available clinical trials click here.